TNF and vascular disorder: The rates of ADR reports of infliximab-related gastrointestinal disorders, cardiac disorders, benign, malignant, and unspecified neoplasms, vascular disorders, and respiratory, thoracic, and mediastinal disorders were significantly higher than those of the other four TNFα inhibitors.